Weight Loss Peptides Semaglutide 99% Purity Peptide CAS 910463-68-2

Contact: WA 852 4689 6985

Semeglutide is a novel GLP-1 analogue that is subcutaneously once a week. Compared with liraglutide, semaglutide has a longer fat chain and increased hydrophobicity, but semaglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only tightly bind albumin, mask the hydrolysis site of DPP-4 enzyme, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.

、Drug Characteristics

• Long-acting effect: Semaglutide binds to albumin, prolonging its half-life and enabling once-weekly dosing, which significantly improves patient adherence.
• Glycemic control mechanism:
  1. （1）Stimulates insulin secretion and inhibits glucagon release in a glucose-concentration-dependent manner.
  2. （2）Delays gastric emptying, reducing postprandial blood glucose fluctuations.
• Weight loss effect: Suppresses appetite via the central nervous system, reduces food intake, and increases satiety, aiding in weight management.
• Cardiovascular protection: Reduces the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
• 
  

2、Application:

• 1. （1）Semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which is more effective in the treatment of type 2 diabetes.
  2. （2）Semaglutide can be used for weight management in people with mild obesity.

3、Indications

• Type 2 diabetes: Used to improve glycemic control, particularly in patients who do not respond adequately to metformin or other oral antidiabetic agents.